Our maturing understanding of the immune responses to GITR agonism in human cancers have clarified novel issues specific to drug development in this space including Ab structure (monospecific and bispecific mAbs and co-stimulatory GITR ligands), Ab valency, and Fc functionality. Here, TNFRSF18 is linked to cancer.